Faculty profile

Jennifer Wyman

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Jennifer Wyman

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
12 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2020.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Community-Based Evaluation Implementation Science Multimethod Opioid Agonist Therapy Overdose Treatment Access

Latest papers

Association between initial benzodiazepine prescribing patterns and time to benzodiazepine discontinuation: A population-based retrospective cohort study.
PLoS medicine · 2026
Association between early methadone dose titration and treatment discontinuation and opioid toxicity: A retrospective cohort study.
PLoS medicine · 2026
Clarifying the evidence and implications of prioritizing extended-release buprenorphine for opioid agonist treatment in Canada's federal correctional system.
Canadian journal of public health = Revue canadienne de sante publique · 2026

All 12 publications

Latest funding

Evaluating the Safety and Effectiveness of Novel Opioid Agonist Therapy Prescribing Practices
CIHR · 2025 · Co-investigator
$650,252
Evaluating the Safety and Effectiveness of Evolving Prescribing Guidance for Opioid Agonist Treatment
CIHR · 2023 · Co-investigator
$562,275
Intensive Virtual Treatment with Remote Abstinence Monitoring for Alcohol Use Disorder
CIHR · 2021 · Co-investigator
$498,714

All 5 grants and awards

12 publications.

Association between initial benzodiazepine prescribing patterns and time to benzodiazepine discontinuation: A population-based retrospective cohort study.

Bozinoff N, Hauck TS, Kleinman RA, Sloan ME, Sproule BA, Vigod SN, Wyman J, Pequeno P, Gomes T

PLoS medicine2026

DOI: 10.1371/journal.pmed.1005126 PMID: 42313778

Association between early methadone dose titration and treatment discontinuation and opioid toxicity: A retrospective cohort study.

Garg R, Luo J, Bozinoff N, Sproule B, Antoniou T, Wyman J, Leece P, Munro C, Besharh J, Gomes T

PLoS medicine2026

DOI: 10.1371/journal.pmed.1004748 PMID: 41955210

Clarifying the evidence and implications of prioritizing extended-release buprenorphine for opioid agonist treatment in Canada's federal correctional system.

Russell C, George TP, Chopra N, Le Foll B, Matheson FI, Kolla G, Wyman J, Fischer B, Bozinoff N, Rehm J, Lange S

Canadian journal of public health = Revue canadienne de sante publique2026

DOI: 10.17269/s41997-026-01186-x PMID: 41954885

Patient and Prescriber characteristics associated with return to daily-dispense methadone: A multilevel cohort study.

Garg R, Ledlie S, McCormack D, Bozinoff N, Wyman J, Sproule B, Leece P, Tadrous M, Smoke A, Munro C, Gomes T

PLOS mental health2025

DOI: 10.1371/journal.pmen.0000442 PMID: 41662135

Assessing the impact of the introduction of generic methadone to the Ontario public drug formulary.

Hamzat B, Wang T, Garg R, Iacono A, Tadrous M, Wu F, Wyman J, Dodd Z, Pinkerton S, Smoke A, Gomes T

The International journal on drug policy2025

DOI: 10.1016/j.drugpo.2025.104918 PMID: 40639197

Initiation and Dose of Methadone Monotherapy vs Combination Therapy, 2015 to 2023.

Garg R, Luo J, Bozinoff N, Sproule B, Antoniou T, Wyman J, Munro C, Gomes T

JAMA network open2025

DOI: 10.1001/jamanetworkopen.2025.27290 PMID: 40815512

Initiation of extended-release buprenorphine in emergency department patients: A retrospective cohort study.

Marion-Bellemare L, Srivastava A, Samson J, Wyman J, Roy DC, McGillis M, Kahan M

The American journal of emergency medicine2025

DOI: 10.1016/j.ajem.2025.04.011 PMID: 40279830

Examining inequities in access to opioid agonist treatment (OAT) take-home doses (THD): A Canadian OAT guideline synthesis and systematic review.

Russell C, Ashley J, Ali F, Bozinoff N, Corace K, Marsh DC, Mushquash C, Wyman J, Zhang M, Lange S

The International journal on drug policy2024

DOI: 10.1016/j.drugpo.2024.104343 PMID: 38554565

Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.

Garg R, Kitchen SA, Men S, Campbell TJ, Bozinoff N, Tadrous M, Antoniou T, Wyman J, Werb D, Munro C, Gomes T

Drug and alcohol dependence2022

DOI: 10.1016/j.drugalcdep.2022.109459 PMID: 35489179

Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.

Kitchen SA, Campbell TJ, Men S, Bozinoff N, Tadrous M, Antoniou T, Wyman J, Werb D, Munro C, Gomes T

The International journal on drug policy2022

DOI: 10.1016/j.drugpo.2022.103644 PMID: 35272107

Something wrong or missing on this profile? Suggest a correction

Jennifer Wyman

Research

Latest papers

Latest funding

Association between initial benzodiazepine prescribing patterns and time to benzodiazepine discontinuation: A population-based retrospective cohort study.

Association between early methadone dose titration and treatment discontinuation and opioid toxicity: A retrospective cohort study.

Clarifying the evidence and implications of prioritizing extended-release buprenorphine for opioid agonist treatment in Canada's federal correctional system.

Patient and Prescriber characteristics associated with return to daily-dispense methadone: A multilevel cohort study.

Assessing the impact of the introduction of generic methadone to the Ontario public drug formulary.

Initiation and Dose of Methadone Monotherapy vs Combination Therapy, 2015 to 2023.

Initiation of extended-release buprenorphine in emergency department patients: A retrospective cohort study.

Examining inequities in access to opioid agonist treatment (OAT) take-home doses (THD): A Canadian OAT guideline synthesis and systematic review.

Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.

Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.

Evaluating the Safety and Effectiveness of Novel Opioid Agonist Therapy Prescribing Practices

Evaluating the Safety and Effectiveness of Evolving Prescribing Guidance for Opioid Agonist Treatment

Intensive Virtual Treatment with Remote Abstinence Monitoring for Alcohol Use Disorder

Alterations in Prescribing of Opioid Agonist Therapy due to the Pandemic (ALT-POP) Study

Remote Treatment of Alcohol Withdrawal: A Pilot Study

Frequent collaborators

Nikki Bozinoff

Tara Gomes

Tony Antoniou

Mina Tadrous

Pamela Leece

Beth Sproule

Shannon Lange

Farihah Ali

Gillian Kolla

Amy Porath

Brian Hutton

Benedikt Fischer

Christopher Mushquash

Bernard Le Foll